Nu-Med Plus (NUMD) Cash & Equivalents Growth (3y) (2014 - 2025)
Nu-Med Plus (NUMD) Cash & Equivalents Growth (3y) (2014 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -9.44% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 19.87% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 8.10% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 36.60% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | 40.99% |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 21.52% |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -0.70% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | 16.75% |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 34.11% |
| 10 | Nu-Med Plus | 1.67 Mn | 1.67 Mn | - | -79.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -79.18% |
| Sep 30, 2025 | 45.84% |
| Mar 31, 2025 | -2.20% |
| Dec 31, 2024 | -41.20% |
| Sep 30, 2024 | -49.75% |
| Jun 30, 2024 | -61.86% |
| Mar 31, 2024 | -64.26% |
| Dec 31, 2023 | -66.95% |
| Sep 30, 2023 | -29.39% |
| Jun 30, 2023 | 69.92% |
| Mar 31, 2023 | 42.49% |
| Dec 31, 2022 | 117.86% |
| Sep 30, 2022 | -75.33% |
| Mar 31, 2022 | -52.23% |
| Dec 31, 2021 | -58.85% |
| Sep 30, 2021 | -42.59% |
| Jun 30, 2021 | -36.79% |
| Mar 31, 2021 | -20.33% |
| Dec 31, 2020 | -18.72% |
| Sep 30, 2020 | -57.47% |